QLT's Eye Drug Gets Orphan Designation In U.S. | OphthalmologyWeb: The Ultimate Online Resource for Ophthalmologists

Tuesday, March 20, 2012

Reuters

Canadian biotechnology company QLT Inc said the U.S. health regulator granted an orphan status to its key eye drug.

A 45 y.o. female comes to the office with a chief complaint of tearing ou and foreign body sensation. Of note are small superficial punctate epitheliopathy diffusely over the central cornea. Her tear film is scanty ou. One would expect her Schirmer’s test
1. >15mm with anesthetic
2. < 10mm="" with="" />
3. >20mm without anesthetic
4. <5mm without="">
Check The Answer

CareCloud Central
CareCloud Central is a medical practice ... view product
Volk iNview
iPhone Fundus Camera The Volk iNview ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us